Back to Authors

Anand, Jasmeet

A5035299131 | I4210091812

Mayo Clinic

Bristol-Myers Squibb (United States)

Citations 3

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e52503e2

10.1097/01.hs9.0000970564.52503.e2

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8089-8091

10.1182/blood-2022-158627

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13256-13258

10.1182/blood-2022-158197